Novo Nordisk Faces 5 Key Questions, Says Analyst
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
Novo Nordisk Expands Drug Discovery Collaboration With Valo Health For Cardiometabolic Diseases
Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...
Novo Nordisk, Valo Health expand drug discovery deal
Danish drugmaker Novo Nordisk (NVO) (OTCPK:NONOF) and AI-focused biotech Valo Health announced Wednesday an agreement to ...